RESUMO
One of the primary indicators of this condition is a painful and migratory dermatitis. Additionally, early signs often include weight loss and diabetes. Patients with glucagonoma commonly first encounter general practitioners or dermatologists. Unfortunately, due to the nonspecific nature of symptoms such as eczema-like dermatitis, weight loss and diabetes, diagnosis is frequently delayed, often by 2-3 years. Consequently, by the time patients are diagnosed, the tumor has usually grown and metastasized, often spreading to the liver. As a result, surgical intervention is often not possible, and treatment options are usually limited to palliative care. However, with early diagnosis of glucagonoma, treatment can be curative. Therefore, it is crucial for medical professionals who initially meet these patients, including dermatologists, general practitioners, endocrinologists, and others, to be aware of this condition to ensure an early diagnosis. By recognizing the signs and symptoms early, doctors can potentially improve patient outcomes and save lives.
Assuntos
Glucagonoma , Neoplasias Pancreáticas , Humanos , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/patologia , Glucagonoma/diagnóstico , Glucagonoma/terapiaRESUMO
PURPOSE: Multiple endocrine neoplasia type 1 (MEN1) is a hereditary endocrine syndrome caused by pathogenic variants in MEN1 tumor suppressor gene. Diagnosis is commonly based on clinical criteria and confirmed by genetic testing. The objective of the present study was to report on a MEN1 case characterized by multiple pancreatic glucagonomas, with particular concern on the possible predisposing genetic defects. METHODS: While conducting an extensive review of the most recent scientific evidence on the unusual glucagonoma familial forms, we analyzed the MEN1 gene in a 35-year-old female with MEN1, as well as her son and daughter, using Sanger and next-generation sequencing (NGS) approaches. We additionally explored the functional and structural consequences of the identified variant using in silico analyses. RESULTS: NGS did not show any known pathogenic variant in the tested regions. However, a new non-conservative variant in exon 4 of MEN1 gene was found in heterozygosity in the patient and in her daughter, resulting in an amino acid substitution from hydrophobic cysteine to hydrophilic arginine at c.703T > C, p.(Cys235Arg). This variant is absent from populations databases and was never reported in full papers: its characteristics, together with the high specificity of the patient's clinical phenotype, pointed toward a possible causative role. CONCLUSION: Our findings confirm the need for careful genetic analysis of patients with MEN1 and establish a likely pathogenic role for the new p.(Cys235Arg) variant, at least in the rare subset of MEN1 associated with glucagonomas.
Assuntos
Glucagonoma , Neoplasia Endócrina Múltipla Tipo 1 , Neoplasias Pancreáticas , Proteínas Proto-Oncogênicas , Adulto , Feminino , Humanos , Glucagonoma/genética , Glucagonoma/diagnóstico , Glucagonoma/patologia , Neoplasia Endócrina Múltipla Tipo 1/genética , Mutação , Neoplasias Pancreáticas/genética , Linhagem , Proteínas Proto-Oncogênicas/genéticaRESUMO
OBJECTIVE: Glucagonoma is a very rare functional pancreatic neuroendocrine tumor (PanNET). We aimed to provide data on the diagnosis, prognosis, and management of patients with glucagonoma. DESIGN AND METHODS: In this retrospective national cohort, we included all patients with glucagonoma, defined by at least 1 major criterion (necrolytic migratory erythema [NME] and/or recent-onset diabetes, and/or weight loss ≥ 5â kg) associated with either glucagonemia > 2 × upper limit of normal or positive glucagon immunostaining. Antisecretory efficacy was defined as partial/complete resolution of glucagonoma symptoms. Antitumor efficacy was assessed according to the time to next treatment (TTNT). RESULTS: Thirty-eight patients were included with median age 58.7 yo, primary PanNET located in the tail (68.4%), synchronous metastases (63.2%). Median Ki-67 index was 3%. Most frequent glucagonoma symptoms at diagnosis were NME (86.8%), weight loss (68.4%), and diabetes (50%). Surgery of the primary PanNET was performed in 76.3% of cases, mainly with curative intent (61.5%). After surgery, complete resolution of NME was seen in 93.8% (n = 15/16). The secretory response rates were 85.7%, 85.7%, 75%, and 60% with surgery of metastases (n = 6/7), chemotherapy (n = 6/7), liver-directed therapy (n = 6/8), and somatostatin analogs (n = 6/10), respectively. All lines combined, longer TTNT was reported with chemotherapy (20.2 months). Median overall survival (OS) was 17.3 years. The Ki-67 index > 3% was associated with shorter OS (hazard ratio 5.27, 95% CI [1.11-24.96], P = .036). CONCLUSION: Patients with glucagonoma had prolonged survival, even in the presence of metastases at diagnosis. Curative-intent surgery should always be considered. Chemotherapy, peptide receptor radionuclide therapy, or liver-directed therapy seems to provide both substantial antitumor and antisecretory efficacies.
Assuntos
Diabetes Mellitus , Neoplasias das Glândulas Endócrinas , Glucagonoma , Eritema Migratório Necrolítico , Tumores Neuroendócrinos , Neoplasias Pancreáticas , Humanos , Pessoa de Meia-Idade , Glucagonoma/diagnóstico , Glucagonoma/terapia , Glucagonoma/complicações , Estudos Retrospectivos , Antígeno Ki-67 , Eritema Migratório Necrolítico/complicações , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/tratamento farmacológico , Neoplasias Pancreáticas/diagnóstico , Tumores Neuroendócrinos/complicações , Redução de PesoRESUMO
BACKGROUND/AIM: Pancreatic neuroendocrine tumors (PNETs) are pancreatic neoplasms with neuroendocrine features, divided into functioning and non-functioning. The non-functioning PNETs are the largest group, and their morbidity is the result of their potential to invade surrounding tissues and metastasize. The functioning PNETs produce hormonal symptoms due to over-secretion of specific hormones. They constitute 1% to 2% of all pancreatic tumors. The use of novel imaging methods has rendered their detection more frequent. Insulinoma, the most common functioning PNET, comprises 35-40% of all functioning PNETs. Its clinical presentation is due to hyperinsulinemia and the subsequent hypoglycemia. Glucagonoma accounts for 5% of all PNETs and is the fourth most frequent functioning PNET, following insulinoma, gastrinoma, and vipoma. Its symptoms are due to the massive secretion of glucagon and ensuing hyperglycemia. The co-existence of two PNETs is a very rare entity. This report aimed to describe cases of concomitant insulinomas and glucagonomas. MATERIALS AND METHODS: A review of the literature was performed using the PubMed database and Cochrane library aiming to identify reported cases of concomitant pancreatic insulinoma and glucagonoma. Specifically, the research was conducted using the keywords, separately and in various combination, including insulinoma, glucagonoma, cystic, pancreatic neuroendocrine tumors and hypoglycemia. Only publications in English were included in the present study. RESULTS: A total of 8 cases of concomitant pancreatic insulinoma and glucagonoma were identified, corresponding to the period 1992-2021. CONCLUSION: Concomitant insulinoma and glucagonoma are rare and challenging. A multidisciplinary approach is necessary for diagnosis, prognosis, and therapy.
Assuntos
Glucagonoma , Hipoglicemia , Insulinoma , Tumores Neuroectodérmicos Primitivos , Tumores Neuroendócrinos , Neoplasias Pancreáticas , Humanos , Insulinoma/diagnóstico , Insulinoma/terapia , Glucagonoma/diagnóstico , Glucagonoma/terapia , Tumores Neuroendócrinos/terapia , Neoplasias Pancreáticas/patologia , Hipoglicemia/diagnóstico , Hipoglicemia/etiologiaRESUMO
This ENETS guidance paper aims to provide practical advice to clinicians for the diagnosis, treatment and follow-up of functioning syndromes in pancreatic neuroendocrine tumours (NET). A NET-associated functioning syndrome is defined by the presence of a clinical syndrome combined with biochemical evidence of inappropriately elevated hormonal levels. Different hormonal syndromes can be encountered in pancreatic NET patients, including insulinoma, gastrinoma as well as the rare glucagonoma, VIPoma, ACTHoma, PTHrPoma, carcinoid syndrome, calcitoninoma, GHRHoma and somatostatinoma. The recommendations provided in this paper focus on the biochemical, genetic and imaging work-up as well as therapeutic management of the individual hormonal syndromes in well-differentiated, grade 1-3, functioning NET with the primary tumour originating in the pancreas, and for specific subtypes also in the duodenum.
Assuntos
Gastrinoma , Glucagonoma , Insulinoma , Tumores Neuroendócrinos , Neoplasias Pancreáticas , Humanos , Tumores Neuroendócrinos/diagnóstico , Tumores Neuroendócrinos/terapia , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/terapia , Insulinoma/diagnóstico , Insulinoma/terapia , Gastrinoma/diagnóstico , Gastrinoma/terapia , Glucagonoma/diagnóstico , Glucagonoma/terapiaRESUMO
Glucagonoma syndrome is an extremely rare paraneoplastic disorder. The key presenting feature is a rash (necrolytic migratory erythema) which can easily be misdiagnosed as a primary skin disorder. Moreover, 50 to 80 % of patients already have metastatic disease at diagnosis. We report a case of a 38-year female presenting with epigastric pain and a skin rash all over the body. Workup revealed a neuroendocrine tumor (NET) of the pancreas, for which she underwent resection, resulting in a complete cure. A follow-up MRI after 8 months showed a hyperintense and arterially enhancing nodular liver lesion which did not show any uptake on the octreotide scan. However, a subsequent biopsy revealed a recurrence of the tumor. This was a unique finding in our case where a highly sensitive octreotide scan failed to identify metastasis, emphasising the importance of biopsy in such cases. Key Words: Glucagonoma, Necrolytic migratory erythema, Alpha-cell adenom.
Assuntos
Glucagonoma , Eritema Migratório Necrolítico , Tumores Neuroendócrinos , Neoplasias Pancreáticas , Feminino , Glucagonoma/complicações , Glucagonoma/diagnóstico , Glucagonoma/cirurgia , Humanos , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/etiologia , Eritema Migratório Necrolítico/patologia , Tumores Neuroendócrinos/complicações , Tumores Neuroendócrinos/diagnóstico , Tumores Neuroendócrinos/cirurgia , Octreotida/uso terapêutico , Pâncreas/patologia , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/patologia , Doenças RarasRESUMO
Glucagonoma is an extremely rare neuroendocrine tumor that arises from pancreatic islet alpha cells. Although glucagonoma is usually accompanied by a variety of characteristic clinical symptoms, early diagnosis is still difficult due to the scarcity of the disease. In this study, we present the cumulative experiences, clinical characteristics and treatments of seven patients diagnosed with glucagonoma during the past 10 years at the First Affiliated Hospital of Xi'an Jiaotong University. The seven patients in our cohort consisted of six females and one male with an average diagnosis age of 40.1 years (range 23-51). The average time from onset of symptoms to diagnosis of glucagonoma was 14 months (range 2-36 months). All the patients visited dermatology first for necrolytic migratory erythema (NME) 7/7 (100%), and other presenting symptoms included diabetes mellitus (DM) 4/7 (57%), stomatitis 2/7 (28%), weight loss 4/7 (57%), anemia 4/7 (57%), diarrhea 1/7 (14%), and DVT1/7 (14%). Plasma glucagon levels were increased in all patients (range 216.92-3155 pg/mL) and declined after surgery. Imaging studies revealed that four of seven patients had liver metastasis. Six of seven patients received surgical resection, and all of them received somatostatin analog therapy. Symptoms improved significantly in 6 out of 7 patients. Three of seven patients died of this disease by the time of follow-up. Our data suggest that if persistent NME is associated with DM and high glucagon levels, timely abdominal imaging should be performed to confirm glucagonoma. Once diagnosed, surgery and somatostatin analogs are effective for symptom relief and tumor control.
Assuntos
Diabetes Mellitus , Glucagonoma , Eritema Migratório Necrolítico , Neoplasias Pancreáticas , Adulto , Feminino , Glucagon , Glucagonoma/complicações , Glucagonoma/diagnóstico , Glucagonoma/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/etiologia , Eritema Migratório Necrolítico/patologia , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/patologia , Somatostatina , Adulto JovemRESUMO
This case concerns an 81-year-old man with weight loss and erythematosquamous plaques, with central clearing and atrophy. Due to a CT scan and blood test the diagnosis necrolytic migratory erythema as a paraneoplastic manifestation of glucagonoma was made. The pathogenesis is not completely elucidated. Early recognition of symptoms is important.
Assuntos
Glucagonoma , Eritema Migratório Necrolítico , Neoplasias Pancreáticas , Idoso de 80 Anos ou mais , Eritema/diagnóstico , Eritema/etiologia , Glucagonoma/complicações , Glucagonoma/diagnóstico , Humanos , Masculino , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/etiologia , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico , Tomografia Computadorizada por Raios X , Redução de PesoAssuntos
Glucagonoma , Eritema Migratório Necrolítico , Neoplasias Pancreáticas , Glucagonoma/complicações , Glucagonoma/diagnóstico , Glucagonoma/cirurgia , Humanos , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/etiologia , Necrose , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/cirurgiaAssuntos
Glucagonoma/cirurgia , Eritema Migratório Necrolítico/etiologia , Pancreatectomia/métodos , Neoplasias Pancreáticas/cirurgia , Glucagon/sangue , Glucagonoma/complicações , Glucagonoma/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Eritema Migratório Necrolítico/patologia , Eritema Migratório Necrolítico/terapia , Invasividade Neoplásica/patologia , Estadiamento de Neoplasias , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/patologia , Doenças Raras , Recuperação de Função Fisiológica , Medição de Risco , Síndrome , Resultado do Tratamento , Redução de PesoAssuntos
Dermatite Esfoliativa/diagnóstico , Dermatomiosite/diagnóstico , Edema/diagnóstico , Dermatoses Faciais/diagnóstico , Glucagonoma/diagnóstico , Neoplasias Pancreáticas/diagnóstico , Dermatite Esfoliativa/etiologia , Dermatomiosite/complicações , Dermatomiosite/imunologia , Diagnóstico Diferencial , Edema/etiologia , Face , Dermatoses Faciais/etiologia , Feminino , Glucagonoma/complicações , Humanos , Pessoa de Meia-Idade , Eritema Migratório Necrolítico/complicações , Eritema Migratório Necrolítico/diagnóstico , Neoplasias Pancreáticas/complicações , Fatores de Transcrição/antagonistas & inibidores , Fatores de Transcrição/imunologiaRESUMO
Autoimmune progesterone dermatitis (APD) is a rare cutaneous disorder with cyclic skin eruptions during the luteal phase of the menstrual cycle. Patients can present with various clinical manifestations, including urticaria and angioedema, erythema multiforme, eczema, fixed drug eruption and centrifugal erythema annulare. In our case, however, the patient's skin lesions mimic necrotic migratory erythema (NME) which is most commonly associated with glucagonoma and rarely with liver disease, inflammatory bowel disease, malnutrition and other tumors. To our knowledge, this is the first case of NME-like APD and is successfully controlled by danazol. This also sheds lights on the etiologic diversity of NME.
Assuntos
Doenças Autoimunes/diagnóstico , Danazol/uso terapêutico , Dermatite/diagnóstico , Antagonistas de Estrogênios/uso terapêutico , Eritema Migratório Necrolítico/diagnóstico , Progesterona/efeitos adversos , Adulto , Doenças Autoimunes/complicações , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/imunologia , Dermatite/complicações , Dermatite/tratamento farmacológico , Dermatite/imunologia , Diagnóstico Diferencial , Feminino , Glucagonoma/complicações , Glucagonoma/diagnóstico , Humanos , Eritema Migratório Necrolítico/tratamento farmacológico , Eritema Migratório Necrolítico/imunologia , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico , Progesterona/imunologia , Pele/imunologia , Pele/patologia , Testes Cutâneos , Resultado do TratamentoAssuntos
Glucagonoma , Eritema Migratório Necrolítico , Neoplasias Pancreáticas , Eritema/etiologia , Glucagonoma/complicações , Glucagonoma/diagnóstico , Humanos , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/etiologia , Necrose , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnósticoRESUMO
RATIONALE: Glucagonoma is a rare type of functional pancreatic neuroendocrine tumor that is characterized by distinctive clinical manifestations; among these, necrolytic migratory erythema represents the hallmark clinical sign of glucagonoma syndrome and is usually presented as the initial complaint of patients. PATIENT CONCERNS: A 30-year-old male patient was admitted to our hospital with a complaint of diffuse erythematous ulcerating skin rash for more than 10 months. He also complained of hyperglycemia and a weight loss of 15âkg in those months. DIAGNOSIS: This patient underwent a contrast-enhanced computed tomography scan which showed a pancreatic body mass measuring approximately 6âcm with low density accompanied by partial calcification in plain scanning images and uneven enhancement in strengthening periods. In addition, laboratory tests indicated elevated fasting blood glucagon (1109âpg/mL, normal range: 50-150âpg/mL) levels. Glucagonoma syndrome was ultimately diagnosed in clinical. INTERVENTION: Spleen-preserving distal pancreatectomy was conducted and postoperative pathology revealed the presence of glucagonoma. OUTCOMES: The patient recovered uneventfully with the glucagonoma syndrome disappeared soon after surgery, and the postoperative plasma glucagon decreased to a normal level. Follow-up showed no recurrence for 5 years since the surgery. LESSONS: The treatment of glucagonoma should be directed according to the stage at which the disease is diagnosed. Surgery is currently the only method available to cure the tumor, although medications are given to patients who present with advanced glucagonoma and who are not candidates for operation. Multidisciplinary therapy and multimodality treatment are advised, although these have been systematically evaluated to a lesser degree.
Assuntos
Glucagonoma/diagnóstico , Eritema Migratório Necrolítico/etiologia , Neoplasias Pancreáticas/diagnóstico , Adulto , Diagnóstico Diferencial , Glucagonoma/complicações , Glucagonoma/diagnóstico por imagem , Glucagonoma/cirurgia , Humanos , Excisão de Linfonodo , Masculino , Pancreatectomia , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/diagnóstico por imagem , Neoplasias Pancreáticas/cirurgia , Baço , Síndrome , Tomografia Computadorizada por Raios XRESUMO
RATIONALE: Glucagonoma is a rare neuroendocrine tumor of the pancreas. Glucagonoma syndrome is often misdiagnosed as other skin lesions by clinicians due to a typical clinical sign of necrolytic migratory erythema (NME) with severe erythematous rash. PATIENT CONCERNS: A 48-year-old female patient was admitted to our department because she presented with unclear recurrent severe erythematous rash. The patient was diagnosed as skin disease. DIAGNOSES: Histopathologic examination revealed a pancreatic glucagonoma. Immnohistochemical staining of tumor tissue was positive for glucagon. INTERVENTIONS: The distal pancreatectomy plus splenectomy was performed in 2017. OUTCOMES: The skin lesions disappeared after surgery. She was followed up and showed no recurrence until now. LESSONS: Clinicians should consider the diagnosis of glucagonoma according to the typical initial symptoms. Early diagnosis is very important to provide a better prognosis. A multidisciplinary approach is effective in patients with unresectable metastatic tumors.
Assuntos
Exantema/complicações , Glucagonoma/complicações , Eritema Migratório Necrolítico/complicações , Neoplasias Pancreáticas/complicações , Diagnóstico Diferencial , Exantema/diagnóstico , Exantema/patologia , Exantema/cirurgia , Feminino , Glucagonoma/diagnóstico , Glucagonoma/patologia , Glucagonoma/cirurgia , Humanos , Pessoa de Meia-Idade , Eritema Migratório Necrolítico/diagnóstico , Eritema Migratório Necrolítico/patologia , Eritema Migratório Necrolítico/cirurgia , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/patologia , Neoplasias Pancreáticas/cirurgiaRESUMO
A 70-year-old man reported progressive weight loss, fatigue and a generalised rash. The rash was consistent with necrolytic migratory erythema, further investigations were performed and the patient was diagnosed with a mass in the tail of the pancreas, in keeping with a localised glucagonoma. Somatostatin analogue therapy was started for symptom control, leading to complete resolution of the skin rash and an improvement in constitutional symptoms. Subsequently, the pancreatic lesion was excised, and pathology assessment confirmed the diagnosis of well-differentiated neuroendocrine tumour with high expression of glucagon compatible with glucagonoma.